JBO-Launched and flying ahead.

TLDR: The Journal of Bone Oncology as discussed by the authors is the first journal devoted to the multidisciplinary management of bone disease in cancer patients and has received 38 manuscripts and to date accepted 25.

Abstract: Welcome to volume two of the Journal of Bone Oncology, the first journal devoted to the multidisciplinary management of bone disease in cancer patients. During the past year, the importance of bone oncology in cancer care has continued to increase. This follows the emergence of further clinical data supporting the use of bone targeted treatments in the adjuvant treatment of early breast cancer [1], [2], the activity of denosumab in delaying the development of bone metastases in castrate resistant prostate cancer [3] and clearer understanding of the risk benefits of denosumab in the prevention of skeletal morbidity in advanced cancer patients with bone metastases. [4], [5] Alongside these important clinical trial results that are already influencing clinical practice, our understanding of the importance of the bone microenvironment and the numerous cellular interactions that take place in the process of metastasis as well as the concept of tumour dormancy has expanded further [6], [7]. We are very excited by the achievements of the journal during this first year, both in terms of the number and quality of manuscripts received. An excellent and unique mix of preclinical science and clinical research in bone oncology has been addressed. So far we have received 38 manuscripts and to date accepted 25. Of the accepted manuscripts, 13 of these were original manuscripts and 9 were reviews, supplemented by two case reports and one editorial. All three issues in volume one have been published on schedule. The high proportion of original manuscripts is particularly gratifying for a new journal and will greatly assist in developing a successful application to Medline later this year, the first critical step to negotiate in order to establish an impact factor and the long term viability of the journal. We are extremely grateful to both our outstanding international Editorial Board who have helped promote the journal and encourage submission of high quality manuscripts and to Elsevier who have ensured the journal has achieved high visibility through Science Direct and provided a wonderfully efficient publication process. This has enabled us on average to review and publish accepted manuscripts within 3 months, providing authors with a rapid route to disseminating their research results. The future for Journal of Bone Oncology is bright and we hope you find the publication informative and relevant. We look forward to receiving your contributions to the Journal.